Bringing Advanced Therapies for Parkinson's Disease to the Clinic: The Scientist's Perspective
Research output: Contribution to journal › Review › Research › peer-review
Documents
- Bringing Advanced Therapies for Parkinson’s Disease to the Clinic
Final published version, 64.7 KB, PDF document
After many years of preclinical development, cell and gene therapies have advanced from research tools in the lab to clinical-grade products for patients, and today they constitute more than a quarter of all new Phase I clinical trials for Parkinson's disease. Whereas efficacy has been convincingly proven for many of these products in preclinical models, the field is now entering a new phase where the functionality and safety of these products will need to stand the test in clinical trials. If successful, these new products can have the potential to provide patients with a one-time administered treatment which may alleviate them from daily symptomatic dopaminergic medication.
Original language | English |
---|---|
Journal | Journal of Parkinson's Disease |
Volume | 11 |
Pages (from-to) | S135-S140 |
Number of pages | 6 |
ISSN | 1877-7171 |
DOIs | |
Publication status | Published - 2021 |
- ATMP, clinical trial, dopaminergic neurons, regenerative therapy, stem cells, transplantation, DOPAMINE NEURONS, PRECLINICAL EFFICACY, CELL TRANSPLANTATION, STEM-CELLS, MODEL, SAFETY, PATHOLOGY, REVEALS, TRIAL
Research areas
Number of downloads are based on statistics from Google Scholar and www.ku.dk
ID: 281275936